The University of Michigan Rogel Cancer Center and the Barbara Ann Karmanos Cancer Institute at Wayne State University have received a prestigious $9.2 million grant from the National Cancer Institute for prostate cancer research.
A secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer finds long-term hormone therapy does more harm than good for many men.
The stable structure of circRNA makes it an ideal candidate for biomarkers because it can be detected in blood or urine, making it potentially useful for cancer diagnosis or prognosis.
While popular beliefs and population data suggest that African-American men are at higher risk of dying from prostate cancer than Caucasian men, a new analysis indicates that African-American patients may have comparatively higher cure rates when treated with radiation therapy.
MENU
